Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

Wietske Kievit, Noortje van Herwaarden, Frank H. J. van den Hoogen, Ronald F. van Vollenhoven, Johannes W. J. Bijlsma, Bart J. F. van den Bemt, Aatke van der Maas, Alfons A. den Broeder

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1939-1944
JournalAnnals of the Rheumatic Diseases
Volume75
Issue number11
DOIs
Publication statusPublished - Nov 2016

Cite this